A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
AstraZeneca
878 participants
Nov 27, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administered as one intravenously (IV) on Day 1 of each 21-day cycle
Administered as one intravenously (IV) on Day 1 of each 21-day cycle
Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Administered as one intravenously (IV) on Day 1 of each 21-day cycle
Locations(282)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06627647